Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation

Journal of Proteome Research

Volumn 10, Issue 7, 2011, Pages 3089-3097

  Improta, Giuseppina ^a   Zupa, Angela ^a   Fillmore, Helen ^b   Deng, Jianghong ^c   Aieta, Michele ^a   Musto, Pellegrino ^a   Liotta, Lance A ^c   Broaddus, William ^b   Petricoin, Emanuel F ^c   Wulfkuhle, Julia D ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN; PROTEIN KINASE B; SMAD PROTEIN; SOMATOMEDIN RECEPTOR; TUMOR PROTEIN;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION;

BRAIN; BRAIN NEOPLASMS; BREAST; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LASERS; LUNG; LUNG NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MICRODISSECTION; MOLECULAR TARGETED THERAPY; ORGAN SPECIFICITY; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPPING; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79959966646     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr200065t     Document Type: Article

References (52)

1. Landis, S. H.; Murray, T.; Bolden, S.; Wingo, P.A.. Cancer statistics, 1999 CA Cancer J. Clin. 1999, 49 (1) 8-31 (Pubitemid 29094959)
2. Nathoo, N.; Chahlavi, A.; Barnett, G. H.; Toms, S. A. Pathobiology of brain metastases J. Clin. Pathol. 2005, 58 (3) 237-242 (Pubitemid 40380315)
3. Patel, R. R.; Mehta, M. P. Targeted therapy for brain metastases: improving the therapeutic ratio Clin. Cancer Res. 2007, 13 (6) 1675-1683 (Pubitemid 46952932)
4. Gril, B.; Evans, L.; Palmieri, D.; Steeg, P. S. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies Eur. J. Cancer 2010, 46 (7) 1204-1210
5. Gondi, V.; Mehta, M. P. Novel insights into the management of brain metastases Curr. Opin. Neurol. 2010, 23 (6) 556-562
6. Sun, M. H. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors Clin. Cancer Res. 2009, 15 (15) 4829-4837
7. Yokota, J. Tumor progression and metastasis Carcinogenesis 2000, 21 (3) 497-503 (Pubitemid 30137935)
8. Paget, S. The distribution of secondary growths in cancer of the breast Lancet 1889, 1, 571-573
9. Palmieri, D. The biology of metastasis to a sanctuary site Clin. Cancer Res. 2007, 13 (6) 1656-1662 (Pubitemid 46957363)
10. Joyce, J. A.; Pollard, J. W. Microenvironmental regulation of metastasis Nat. Rev. Cancer 2009, 9 (4) 239-252
11. Grinburg-Rashi, H. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain Clin. Cancer Res. 2009, 15 (5) 1755-1761
12. Kang, Y. A multigenic program mediating breast cancer metastasis to bone Cancer Cell 2003, 3 (6) 537-549 (Pubitemid 36808649)
13. Minn, A. J. Genes that mediate breast cancer metastasis to the lung Nature 2005, 436 (7050) 518-524 (Pubitemid 41112921)
14. Bos, P. D. Genes that mediate breast cancer metastasis to the brain Nature 2009, 459 (7249) 1005-1009
15. Pierobon, M. P. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker Clin. Colorectal Cancer 2009, 8 (2) 110-117
16. Klein, A. Identification of brain- and bone-specific breast cancer metastasis genes Cancer Lett. 2009, 276 (2) 212-220
17. Weigelt, B. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res. 2005, 65 (20) 9155-9158 (Pubitemid 41507977)
18. Steeg, P. S.; Theodorescu, D. Metastasis: a therapeutic target for cancer Nat. Rev. Clin. Oncol. 2008, 5 (4) 206-219 (Pubitemid 351493680)
19. Kikuchi, T. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray Int. J. Oncol. 2006, 28 (4) 799-805
20. Grubb, R. L. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures J. Proteome Res. 2009, 8 (6) 3044-3054
21. Petricoin, E. F., III Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy J. Clin. Oncol. 2005, 23 (15) 3614-3621
22. Sheehan, K. M. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma Mol. Cell. Proteomics 2005, 4 (4) 346-355 (Pubitemid 40590555)
23. Gomez-Roca, C. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites J. Thorac. Oncol. 2009, 4 (10) 1212-1220
24. Italiano, A. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors Ann. Oncol. 2006, 17 (6) 981-985 (Pubitemid 43778990)
25. Gygi, S. P.; Rochon, Y.; Franza, B. R.; Aebersold, R. Correlation between protein and mRNA abundance in yeast Mol. Cell. Biol. 1999, 19 (3) 1720-1730 (Pubitemid 29098230)
26. Anderson, L.; Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver Electrophoresis 1997, 18 (3-4) 533-537 (Pubitemid 27174443)
27. Shankavaram, U. T. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study Mol. Cancer Ther. 2007, 6 (3) 820-832 (Pubitemid 46554552)
28. Scott, J. D.; Pawson, T. Cell signaling in space and time: where proteins come together and when they're apart Science 2009, 326 (5957) 1220-1224
29. Huang, S. M.; Harari, P. M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Invest. New Drugs 1999, 17 (3) 259-269 (Pubitemid 30037958)
30. Ono, M. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer Int. J. Clin. Oncol. 2009, 14 (1) 48-52
31. Tham, Y. L. Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer 2006, 107 (4) 696-704
32. Hicks, D. G. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR Am. J. Surg. Pathol. 2006, 30 (9) 1097-1104 (Pubitemid 44299342)
33. Rusnak, D. W. The effects of the novel, reversible epidermal growth factor receptor/Erb-B-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol. Cancer Ther. 2001, 1 (2) 85-94
34. Paweletz, C. P. Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Oncogene 2001, 20 (16) 1981-1989
35. Wulfkuhle, J. D. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy J. Proteome Res. 2008, 7 (4) 1508-1517
36. Silvestri, A. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing Lab. Invest. 2010, 90 (5) 787-796
37. Piyathilake, C. J. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung Clin. Cancer Res. 2002, 8 (3) 734-744 (Pubitemid 34742102)
38. Scagliotti, G. V.; Selvaggi, G.; Novello, S.; Hirsch, F. R. The biology of epidermal growth factor receptor in lung cancer Clin. Cancer Res. 2004, 10 (12,Pt 2) 4227S-4232S (Pubitemid 38812451)
39. Ohasak, Y. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol. Rep. 2000, 7 (3) 603-607
40. Slamon, D. J. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989, 244 (4905) 707-712 (Pubitemid 19147683)
41. Press, M. F. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials Clin. Cancer Res. 2005, 11 (18) 6598-6607 (Pubitemid 41339000)
42. Chen, A. M. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain Cancer 2007, 109 (8) 1668-1675 (Pubitemid 46595704)
43. Omuro, A. M. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 2005, 103 (11) 2344-2348 (Pubitemid 40686581)
44. Lin, N. U.; Winer, E. P. Brain metastases: the HER2 paradigm Clin. Cancer Res. 2007, 13 (6) 1648-1655 (Pubitemid 46952930)
45. Petricoin, E. F., III Phosphoprotein signal pathway mapping: Akt/mTOR pathway activation association with childhood rhabdomyosarcoma survival Cancer Res. 2007, 67 (7) 3431-3434
46. Lin, N. U. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer 2008, 113 (10) 2638-2645
47. Palmieri, D. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain Cancer Res. 2007, 67 (9) 4190-4198 (Pubitemid 46815065)
48. Gril, B. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J. Natl. Cancer Inst. 2008, 100 (15) 1092-1103
49. Lin, N. U. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin. Cancer Res. 2009, 15 (4) 1452-1459
50. Katayama, T. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib J. Thorac. Oncol. 2009, 4 (11) 1415-1419
51. Olmez, I. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastases Lung Cancer 2010, 70 (2) 174-179
52. Cicenas, J. The potential role of Akt phosphorylation in human cancers Int. J. Biol. Markers 2008, 23 (1) 1-9 (Pubitemid 351715539)